116 related articles for article (PubMed ID: 204583)
1. Establishment of paired tumor cells and autologous virus-transformed cell lines to define humoral immune responses in melanoma and sarcoma patients.
Saxton RE; Irie RF; Ferrone S; Pellegrino MA; Morton DL
Int J Cancer; 1978 Mar; 21(3):299-306. PubMed ID: 204583
[TBL] [Abstract][Full Text] [Related]
2. Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells.
Topalian SL; Rivoltini L; Mancini M; Ng J; Hartzman RJ; Rosenberg SA
Int J Cancer; 1994 Jul; 58(1):69-79. PubMed ID: 7516926
[TBL] [Abstract][Full Text] [Related]
3. Tissue specificity of anti melanoma monoclonal antibodies analyzed on cell lines.
Johnson JP; Riethmüller G
Hybridoma; 1982; 1(4):381-5. PubMed ID: 6208134
[TBL] [Abstract][Full Text] [Related]
4. The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens.
Darrow TL; Slingluff CL; Seigler HF
J Immunol; 1989 May; 142(9):3329-35. PubMed ID: 2785141
[TBL] [Abstract][Full Text] [Related]
5. Analysis of two human monoclonal antibodies against melanoma.
Yeilding NM; Gerstner C; Kirkwood JM
Int J Cancer; 1992 Dec; 52(6):967-73. PubMed ID: 1459738
[TBL] [Abstract][Full Text] [Related]
6. The serologic response of patients with stage II melanoma to allogeneic melanoma cell vaccines.
Livingston PO; Kaelin K; Pinsky CM; Oettgen HF; Old LJ
Cancer; 1985 Nov; 56(9):2194-200. PubMed ID: 4052966
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. Implications for the study of tumor antigens.
Albino AP; Lloyd KO; Houghton AN; Oettgen HF; Old LJ
J Exp Med; 1981 Dec; 154(6):1764-78. PubMed ID: 6976407
[TBL] [Abstract][Full Text] [Related]
8. Demonstration of specific serologic reactivity in human osteosarcoma.
Sindelar WF
Cancer; 1983 Feb; 51(3):444-51. PubMed ID: 6185204
[TBL] [Abstract][Full Text] [Related]
9. Cell surface antigens of human malignant melanoma. II. Serological typing with immune adherence assays and definition of two new surface antigens.
Shiku H; Takahashi T; Oettgen HF
J Exp Med; 1976 Oct; 144(4):873-81. PubMed ID: 978138
[TBL] [Abstract][Full Text] [Related]
10. Isolation and immunochemical characterization of antibodies from the sera of cancer patients which are reactive against human melanoma cell membranes by affinity chromatography.
Gupta RK; Silver HK; Reisfeld RA; Morton DL
Cancer Res; 1979 May; 39(5):1683-95. PubMed ID: 427806
[TBL] [Abstract][Full Text] [Related]
11. Human IgG and IgM monoclonal antibodies against autologous melanoma produced by Epstein-Barr-virus-transformed B lymphocytes.
Kirkwood JM; Robinson JE
Cancer Immunol Immunother; 1990; 32(4):228-34. PubMed ID: 2175672
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic T cell recognition of Epstein-Barr virus-infected B cells. III. Establishment of HLA-restricted cytotoxic T cell lines using interleukin 2.
Wallace LE; Rowe M; Gaston JS; Rickinson AB; Epstein MA
Eur J Immunol; 1982 Dec; 12(12):1012-8. PubMed ID: 6297919
[TBL] [Abstract][Full Text] [Related]
13. Common expression of melanoma tumor-associated antigens recognized by human tumor infiltrating lymphocytes: analysis by human lymphocyte antigen restriction.
Hom SS; Topalian SL; Simonis T; Mancini M; Rosenberg SA
J Immunother (1991); 1991 Jun; 10(3):153-64. PubMed ID: 1868040
[TBL] [Abstract][Full Text] [Related]
14. Humoral and cellular immune reactions 'in vitro' against allogeneic and autologous human melanoma cells.
Peter HH; Kalden JR; Seeland P; Diehl V; Eckert G
Clin Exp Immunol; 1975 May; 20(2):193-207. PubMed ID: 765012
[TBL] [Abstract][Full Text] [Related]
15. Rheumatoid factor in melanoma patients: alterations of humoral tumor immunity in vitro.
Giuliano AE; Irie R; Morton DL
Cancer; 1979 May; 43(5):1624-9. PubMed ID: 376097
[TBL] [Abstract][Full Text] [Related]
16. In vitro growth of B lymphocytes infiltrating human melanoma tissue by transformation with EBV: evidence for secretion of anti-melanoma antibodies by some transformed cells.
Watson DB; Burns GF; Mackay IR
J Immunol; 1983 May; 130(5):2442-7. PubMed ID: 6300247
[TBL] [Abstract][Full Text] [Related]
17. Cloned human cytotoxic T lymphocyte (CTL) lines reactive with autologous melanoma cells. I. In vitro generation, isolation, and analysis to phenotype and specificity.
de Vries JE; Spits H
J Immunol; 1984 Jan; 132(1):510-9. PubMed ID: 6197458
[TBL] [Abstract][Full Text] [Related]
18. Serological survey of normal humans for natural antibody to cell surface antigens of melanoma.
Houghton AN; Taormina MC; Ikeda H; Watanabe T; Oettgen HF; Old LJ
Proc Natl Acad Sci U S A; 1980 Jul; 77(7):4260-4. PubMed ID: 6933476
[TBL] [Abstract][Full Text] [Related]
19. The novel panel assay to define tumor-associated antigen-binding antibodies in patients with metastatic melanomas may have diagnostic value.
Kotlan B; Liszkay G; Blank M; Csuka O; Balatoni T; Toth L; Eles K; Horvath S; Naszados G; Olasz J; Banky B; Toth J; Godeny M; Marincola FM; Kasler M; Shoenfeld Y
Immunol Res; 2015 Feb; 61(1-2):11-23. PubMed ID: 25480739
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus-induced lymphoblastoid cell lines from seropositive adult donors and their HLA-antigens.
Akiyama N; Ohsawa N; Kusaba R; Inou T; Takada M
Jpn J Exp Med; 1981 Feb; 51(1):1-7. PubMed ID: 6273617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
